Alkermes Transitions To Novel R&D Products With Learnings From COVID-19

 
• By Joseph Haas

Built on established products and royalties from drug delivery technology, Alkermes is getting ready to launch its first novel product. Scrip talked to CEO Richard Pops about the preparations.

Colorful leaves
Transforming firm Alkermes has several major inflection points coming up

More from Business

More from Scrip